Press Releases July 15, 2026 08:00 AM

VTAK Announces Preliminary Second Quarter Record Revenue in Excess of $1 million

Catheter Precision reports preliminary Q2 record revenue surpassing $1 million, driven by strong growth in MedTech and Flyte Vision Jet aviation segments

By Hana Yamamoto
Share
Twitter Reddit Facebook LinkedIn
VTAK

Catheter Precision, Inc. announced preliminary unaudited record revenues of $1,037,000 for Q2 2026, reflecting significant growth in both its MedTech cardiac electrophysiology segment and its Flyte Vision Jet aviation segment. The aviation business grew 61% sequentially, and the MedTech segment increased 27% compared to Q2 2025. The company anticipates continuing strong momentum, expecting to move from million-dollar quarters to million-dollar months by year-end.

VTAK Announces Preliminary Second Quarter Record Revenue in Excess of $1 million
VTAK
Summarize with
ChatGPT Perplexity Claude Grok Gemini

Key Points

  • Preliminary Q2 2026 revenue exceeded $1 million, a record for the company.
  • Flyte Vision Jet segment grew 61% sequentially, contributing $767,000 to revenue.
  • MedTech segment grew 27% year-over-year, reflecting strong demand in cardiac electrophysiology devices.
  • Catheter Precision is actively expanding its aviation fleet and plans to increase operational capacity through pilot recruitment and certification.

Flyte Vision Jet Segment up 61% sequentially over Q1, 2026, contributing $767,000

MedTech segment up 27% over Q2 2025

FORT MILL, S.C., July 15, 2026 (GLOBE NEWSWIRE) -- Catheter Precision, Inc. (VTAK: NYSE/American), today announced preliminary unaudited record revenues of $1,037,000 for the quarter ended June 30, 2026, including both the MedTech segment and the Flyte Vision Jet segment.

David Jenkins, CEO of Catheter Precision, Inc., commented, “We are extremely pleased as to the revenue growth of the company, including the growth in both segmented areas. We are especially pleased with the acquisition of Fly Flyte, Inc., and its promise for the future. As we bring on additional Vision Jets into our fleet, and recruit, train, and certify new pilots, we believe our company should be poised to transition from a million-dollar quarter to a million-dollar month before the end of the year. In fact, our preliminary revenue for just the first two weeks of July (2026) is over $400,000.”

Mr. Jenkins continued, “We continue to work with an outside investment bank to enhance shareholder value through alternative scenarios envisioned for our MedTech segment. Cardiac electrophysiology is one of the largest growth areas in medical devices today, and we believe our technology offers substantial value to physicians and associated patient care. Our goal is to solidify our MedTech plans over the next several months.”

About VTAK
The MedTech segment, Catheter Precision, is an innovative U.S.-based medical device company bringing new solutions to market to improve the treatment of cardiac arrhythmias. It is focused on developing groundbreaking technology for electrophysiology procedures by collaborating with physicians and continuously advancing its products.

The aviation segment, Flyte, is a private aviation company operating a growing fleet of Cirrus Vision Jets and providing efficient short-haul travel solutions throughout the United States.

Flight operations are conducted through Flyte's wholly owned subsidiary, Ponderosa Air, LLC, an FAA-certified Part 135 air carrier. With certified aircraft, active revenue-generating operations, and scalable fleet expansion underway, Flyte is building disciplined aviation infrastructure designed to deliver a faster, safer, and more efficient alternative to traditional private charter travel.

Preliminary Second Quarter 2026 Results

This press release sets forth certain preliminary estimates of financial and operating results that we expect to report for the second quarter ended June 30, 2026. We are currently in the process of finalizing our financial results for the June 30, 2026 second quarter, and the preliminary estimated financial information presented above reflects various assumptions and estimates based upon preliminary information available to us as of the date of this press release. This information should not be viewed as a substitute for full unaudited financial statements prepared in accordance with accounting principles generally accepted in the United States for the second quarter ended June 30, 2026. Our independent registered public accounting firm has not reviewed this preliminary estimated financial information. As a result, it remains in all cases subject to change pending finalization. Items or events may be identified or occur after issuance of these preliminary results due to the completion of operational and financial closing procedures. In addition, final adjustments and other developments may arise that would require us to make material adjustments to this preliminary financial information.

Cautionary Note Regarding Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Forward-looking statements can be identified by words such as “believe,” “anticipate,” “may,” “might,” “can,” “could,” “continue,” “depends,” “expect,” “expand,” “forecast,” “intend,” “predict,” “plan,” “rely,” “should,” “will,” “may,” “seek,” or the negative of these terms and other similar expressions, although not all forward-looking statements contain these words.  These forward-looking statements include, but are not limited to, statements regarding our belief our company should be poised to transition from a million-dollar quarter to a million-dollar month before the end of the year. These and other risks are detailed in the Company’s filings with the Securities and Exchange Commission, including its most recent Forms 10-K and 10-Q. The Company undertakes no obligation to update any forward-looking statements except as required by law.

CONTACTS:

Investor Relations
973-691-2000
[email protected]

# # #


Risks

  • Financial results are preliminary, unaudited, and subject to change upon finalization, posing a risk of adjustments that could impact perceived performance.
  • Forward-looking statements about transitioning to million-dollar months and MedTech strategic plans are uncertain and depend on market and operational execution.
  • Investment in expansion of aviation fleet and MedTech segment involves execution risks, regulatory compliance, and market acceptance uncertainty.

More from Press Releases

HII’s Ingalls Shipbuilding Erects First Grand Blocks Built by Distributed Shipbuilding Partners on Thad Cochran (DDG 135) Jul 15, 2026 Fr8Tech Advances AI-Native Transformation, Reduces Workforce and Raises Additional Capital Jul 15, 2026 Hotel dining, checked in: OpenTable reveals how hotel restaurants are shaping Canadian dining and travel plans Jul 15, 2026 Performance Shipping Inc. Announces Completion of Sale and Delivery of M/T P. Sophia to New Owners Jul 15, 2026 Virtuix Selected for NASA’s Moon and Mars Exploration Analog Mission Jul 15, 2026